

Attorney Docket No. LeA 35 926

ORIGINAL

Jew B.
S
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Feurer, et al.

Application No.: 10/521,538

Group No.: 1624

Filed: 14 January 2005

Examiner: Deepak Rao

For: Novel 2,5-Disubstituted Pyrimidine Derivatives

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 10 April 2006



Gil Cunha

COMMISSIONER FOR PATENTS
P.O. Box 1450
ALEXANDRIA, VA 22202

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

**TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed **after** three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but **before** the mailing date of either
 - (1) a final action under section 1.113 or
 - (2) a notice of allowance under section 1.311 or
 - (3) any other action closing prosecutionwhichever occurs first.

Attorney Docket No. LeA 35 926

FEE


2. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

3. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 42,972

Telephone: (203) 812-6450


Date: 10 April 2006

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office					Serial No. 10/521,538	Group Art Unit 1624	Filing Date 14 Jan. 2005	Atty. Docket No. LeA 35 926
1 of 3							Applicant(s) Feurer, et al.			
INFORMATION DISCLOSURE CITATION										

O I P E
APR 13 2006
U.S. PATENT AND TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS														
Examiner Initials	No.	DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F1	9	8	1	6	2	2	3	23/04/98	DE				X
	F2	9	8	1	6	5	0	7	23/04/98	DE				X
	F3	9	8	2	3	6	1	9	04/06/98	DE				X
	F4	0	0	0	6	5	6	7	10/02/00	DE				X
	F5	0	0	0	6	5	6	8	10/02/00	DE				X
	F6	0	0	0	6	5	6	9	10/02/00	DE				X
	F7	0	0	2	1	9	5	4	20/04/00	DE				X
	F8	0	2	0	4	2	2	9	17/01/02	US				
	F9	0	2	0	4	3	0	0	17/01/02	JP				X
	F10	0	2	0	4	3	0	1	17/01/02	DE				X
	F11	0	2	0	4	3	0	2	17/01/02	US				

EXAMINER	DATE CONSIDERED
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/521,538
Filing Date	14 January 2005
First Named Inventor	Feurer, et al.
Art Unit	1624
Examiner Name	Deepak Rao
Attorney Docket Number	LeA 35 926

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	YAMADA, et al., Role of Nitric Oxide and Cyclic GMP in the Dizocilpine-Induced Impairment of Spontaneous Alteration Behavior in Mice, Neuroscience, vol. 74, no. 2, 1996, pp. 365-374	
	R2	WU, et al., YC-1, A Novel Activator of Platelet Guanylate Cyclase, Blood, vol. 84, no. 12, 1994 pp. 4226-4233	
	R3	MÜLSCH, et al., Effect of YC-1, An NO-Independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, On Smooth Muscle Responsiveness to Nitrovasodilators, British Journal of Pharmacy, vol. 120, 1997, pp. 681-689	
	R4	GOLDBERG, et al., Stimulation of Human Platelet Guanylate Cyclase by Fatty Acids, Journal of Biological Chemistry, vol. 252, no. 4, 1977, pp. 1279-1285	
	R5	PETTIBONE, et al., A Structurally Novel Stimulator of Guanylate Cyclase with Long-Lasting Hypotensive Activity in the Dog, European Journal of Pharmacology, vol. 116, 1985, pp. 307-312	
	R6	YU, et al., Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta, British Journal of Pharmacology, vol. 114, 1995, pp. 1587-1594	
	R7	KRAUSE, et al., Improved Procedures for the Palladium-Catalyzed Coupling of Terminal Alkynes with Aryl Bromides (Sonogashira Coupling), Journal of Organic Chemistry, vol. 63, 1998, pp. 8551-8553	
	R8	SUZUKI, Organoborates in New Synthetic Reactions, Accounts of Chemical Research, vol. 15, 1982, pp. 178-184	
	R9	MIYURA, et al., Palladium-Catalyzed Inter- and Intramolecular Cross-Coupling Reactions of B-Alkyl-9-borabicyclo[3.3.1]nonane Derivatives with 1-Halo-1-alkenes or Haloarenes. Syntheses of Functionalized Alkenes, Arenes, and Cycloalkenes via a Hydroboration-Coupling Sequence, Journal of the American Chemical Society, vol. 111, 1989, pp. 314-321	
	R10	BUCHWALD, et al., Palladium-catalyzed amination of Aryl halides and Sulfonates, Journal of Organometallic Chemistry, vol. 576, 1999, pp. 125-146	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<i>Complete if Known</i>			
				Application Number		10/521,538	
				Filing Date		14 January 2005	
				First Named Inventor		Feurer et al.	
				Art Unit		1624	
				Examiner Name		Deepak Rao	
Sheet	3	of	3	Attorney Docket Number		LeA 35 926	

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.